by Truveta staff | Dec 6, 2024 | Data
New results released this week from the SURMOUNT-5 clinical trial comparing tirzepatide (Zepbound) to semaglutide (Wegovy) are closely aligned to Truveta Research’s GLP-1 comparative effectiveness study, initially shared more than a year ago on November 27, 2023 and...
by Truveta staff | Feb 22, 2024 | Data, Technology
The National Academy of Medicine has estimated that less than half of all medical care in the US is supported by adequate evidence of effectiveness. The proliferation of treatment options in some disease states and the rising costs of many of those treatments have...
by Truveta staff | Oct 24, 2023 | Research
Each year, approximately 900,000 patients in the United States are affected by PE, a blood clot causing a blockage in one or more pulmonary arteries in the lungs and a leading cause of in-hospital death in the U.S. Acute pulmonary embolism (PE) is the third-leading...
by Truveta Research | May 9, 2023 | Research, Research Insights
This blog is an extension of our poster presented at ISPOR, titled Real-World Effectiveness of SGLT2 Inhibitors Vs Metformin as First-Line Therapy in Type 2 Diabetes. Individuals with type 2 diabetes mellitus (T2DM) have a higher risk of cardiovascular disease...
